Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug Tralokinumab's eye risks under the microscope

NCT ID NCT05682976

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 100 adults with atopic dermatitis (eczema) who were prescribed tralokinumab. Researchers tracked how many developed eye problems like conjunctivitis within 4 months of starting the drug. The goal was to better understand these side effects in real-world use, not to test if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tralokinumab
What this could lead to
If successful, this study could help doctors better understand and manage eye side effects of tralokinumab, improving treatment safety for eczema patients.
What could go wrong
This is a small, completed observational study (100 participants) that only tracks side effects, not treatment effectiveness. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jun 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated for AD requiring systemic treatment with Tralokinumab. In order to keep a representative overview of all patients with atopic dermatitis, the number of patients included after Dupilumab failure will be limited to 25%. For patients previously treated with Dupilumab, a washout period of up to one month should be observed prior to inclusion to avoid the reporting of ophthalmological events at baseline still related to Dupilumab treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (\> 18 years), * Patients with atopic dermatitis, * Patients indicated for treatment with Tralokinumab * Patients able to express non opposition. Exclusion Criteria: * Patients who have stopped Dupilumab for less than one month, * Patients under guardianship or trusteeship * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema conjunctivitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • CHRU de Lille

    Lille, France

  • CHU de Bordeaux

    Bordeaux, France

  • CHU de Brest

    Brest, France

  • CHU de Clermont Ferrand

    Clermont-Ferrand, France

  • CHU de Nantes

    Nantes, France

  • CHU de Rouen

    Rouen, France

  • CHu de Dijon

    Dijon, France

  • CHu de Poitiers

    Poitiers, France

  • CHu de Rennes

    Rennes, France

  • Hospice Civil de Lyon

    Lyon, France

  • Hôpital Saint Louis

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.